Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/188962
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Álvarez Palomo, Ana Belén | - |
dc.contributor.author | Veiga, Anna | - |
dc.contributor.author | Raya, Angel | - |
dc.contributor.author | Codinach, Margarita | - |
dc.contributor.author | Torrents, Silvia | - |
dc.contributor.author | Ponce Verdugo, Laura | - |
dc.contributor.author | Rodriguez Aierbe, Clara | - |
dc.contributor.author | Cuellar, Leopoldo | - |
dc.contributor.author | Alenda, Raquel | - |
dc.contributor.author | Arbona, Cristina | - |
dc.contributor.author | Hernández Maraver, Dolores | - |
dc.contributor.author | Fusté, Cristina | - |
dc.contributor.author | Querol Giner, Sergi | - |
dc.date.accessioned | 2022-09-12T13:45:29Z | - |
dc.date.available | 2022-09-12T13:45:29Z | - |
dc.date.issued | 2022-08-12 | - |
dc.identifier.issn | 1757-6512 | - |
dc.identifier.uri | http://hdl.handle.net/2445/188962 | - |
dc.description.abstract | Background The increasing number of clinical trials for induced pluripotent stem cell (iPSC)-derived cell therapy products makes the production on clinical grade iPSC more and more relevant and necessary. Cord blood banks are an ideal source of young, HLA-typed and virus screened starting material to produce HLA-homozygous iPSC lines for wide immune-compatibility allogenic cell therapy approaches. The production of such clinical grade iPSC lines (haplolines) involves particular attention to all steps since donor informed consent, cell procurement and a GMP-compliant cell isolation process. Methods Homozygous cord blood units were identified and quality verified before recontacting donors for informed consent. CD34+ cells were purified from the mononuclear fraction isolated in a cell processor, by magnetic microbeads labelling and separation columns. Results We obtained a median recovery of 20.0% of the collected pre-freezing CD34+, with a final product median viability of 99.1% and median purity of 83.5% of the post-thawed purified CD34+ population. Conclusions Here we describe our own experience, from unit selection and donor reconsenting, in generating a CD34+ cell product as a starting material to produce HLA-homozygous iPSC following a cost-effective and clinical grade-compliant procedure. These CD34+ cells are the basis for the Spanish bank of haplolines envisioned to serve as a source of cell products for clinical research and therapy. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Springer Science and Business Media LLC | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1186/s13287-022-02961-6 | - |
dc.relation.ispartof | Stem Cell Research & Therapy, 2022, vol. 13, issue. 1 | - |
dc.relation.uri | https://doi.org/10.1186/s13287-022-02961-6 | - |
dc.rights | cc by (c) Álvarez Palomo, Ana Belén et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Bancs de sang | - |
dc.subject.classification | Sang fetal | - |
dc.subject.other | Blood banks | - |
dc.subject.other | Fetal blood | - |
dc.title | Public Cord Blood Banks as a source of starting material for clinical grade HLA-homozygous induced pluripotent stem cells | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-08-25T11:49:59Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35962457 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s13287-022-02961-6.pdf | 1.14 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License